Pharmacogenomics of Heparin-Induced Thrombocytopenia
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18 years of age or older
• Ability to give informed consent
• Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT
• Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing
Locations
United States
Arizona
Banner University Medical Center - Tucson
RECRUITING
Tucson
Contact Information
Primary
Jason H Karnes, PharmD, PhD
karnes@pharmacy.arizona.edu
520-626-1447
Backup
Talin A Robinson-Catalan, MS
talinrobinson@arizona.edu
520-278-6114
Time Frame
Start Date: 2016-03
Estimated Completion Date: 2026-07
Participants
Target number of participants: 125
Treatments
Blood Draw
A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
Related Therapeutic Areas
Sponsors
Collaborators: American College of Clinical Pharmacy
Leads: University of Arizona